In contrast to the unfavorable role of HLA-A2, in a recent phase I trial from our group, we noticed that, among PCa patients vaccinated with a CD4+ T cell-stimulating HER-2/neu hybrid-peptide, the HLA-A*24 allele expression conferred a better clinical outcome [24,25]. The gene discussed is HLA-A; the disease is posterior cortical atrophy.